ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue89,91247,15941,097
Cost of Revenue---
Gross Profit89,91247,15941,097
Operating Expenses
Research Development390,635382,392276,495
Selling General and Administrative199,36589,35460,610
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-500,088-424,587-296,008
Income from Continuing Operations
Total Other Income/Expenses Net9,21414,4795,935
Earnings Before Interest and Taxes-490,874-410,108-290,073
Interest Expense---
Income Before Tax-490,874-410,108-290,073
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-490,874-410,108-290,073
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-490,874-410,108-290,073
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-490,874-410,108-290,073